• How Broadening The Analysis Of Compound Factors Allows For Predictive Solubility Solutions
    How Broadening The Analysis Of Compound Factors Allows For Predictive Solubility Solutions

    The Biopharmaceutics Classification System (BCS), developed by the U.S. Food and Drug Administration to simplify and accelerate the drug development process, helps companies when they file for bioequivalence of dosage forms based on in vitro dissolution testing. The objective of the BCS system is to predict in vivo performance of drugs from in vitro measurements of solubility and permeability. The system has evolved to classify low-soluble drugs according to their permeability (BCS Class II or IV). A compound’s classification (I through IV) is indicative of its potential bioavailability.

  • Implications Of Inaccurate Forecasting On Biologics Drug Substance Manufacturing

    To better understand the issues that biopharmaceutical companies face when planning for clinical and commercial biologic drug substance manufacturing and supply needs, ORC International conducted interviews with biopharmaceutical executives in North America and Europe who consistently utilize forecasts for drug substance and commercial manufacturing planning for biologics. This research explored the causes, consequences, and potential solutions to forecasting challenges specifically related to biologic drug substance manufacturing.

  • Impact Of Incorrect Forecasts On New Drug Product Launches

    Pharmaceutical company marketing executives have become more accurate in positioning their new product in the marketplace, profiling prescribers, and understanding and responding to the reimbursement landscape. What is still a quagmire for pharma companies is predicting the actual demand for products and the timing of that demand.

  • How To Live With Uncertain Pharma Demand Forecasts

    Demand forecasts are often wrong because they are developed to inform manufacturing commitments as many as four to five years before product launch. As contractual relationships with CMOs are driven by forecasts inaccurate forecasts can “result in unfavorable pricing, financial penalties, and inappropriate capacity,” according to Jim Miller, President of PharmSource, a pharmaceutical industry contract manufacturing intelligence firm.

  • Streamlining Pharm Drug Development: Yes, It’s Time.

    The path from molecule to market isn’t getting any easier. The costs of drug development over the last five years have continued to rise while sales during the same timeframe have tumbled. This calls for streamlining of today’s current drug development process. Read how today’s experts think this can be accomplished.

More From Featured Articles


Drug Product Development Services Drug Product Development Services

Considering that 90% of drug candidates have bioavailability issues, making sure your program is prepared for all phases of clinical trials from the very start is the fast way forward. Patheon Solubility Enhancement Services approaches BCS II and IV drug substance solubility issues a fundamentally different way that identifies the solubility enhancement technologies most likely to work before you get started. That helps eliminate rework and worry later on.

Monoclonal Antibody
The fluorochrome conjugated anti-CD56 monoclonal antibody is available both labeled and unlabeled with FITC-biotin, phycoerythrin, or allophycocyanin for low cytometry and indirect immunofluorescence applications...
Automated Extraction System Automated Extraction System
The SPE-DEX 4790 automated extraction system is a fully-automated solid phase extraction (SPE) system for drinking water, wastewater, and solid waste applications that is designed for speed, accuracy, and consistency of SPE extractions...
CD40L Research Tools
Research tools are available for the CD40 ligand, which is said to play an important role in
Multiskan EX
Multiskan - Microplate Photometer
Drug Process Development Drug Process Development

Althea’s complete range of drug Process Development capabilities offers the tools to address your needs. We develop processes for producing small quantities of proteins for early testing or establish robust, reliable and scalable processes that enable a strong commercial advantage. Althea also provides access to a proprietary drug delivery platform, called Crystalomics® technology, for the development of alternative drug delivery formulations of second generation drug substances.

More Featured Products


How to Write SOPs That are GCP Compliant and Implementable July 12, 2016
1pm-2:30pm EDT, Online Training
Preparing eCTD Submissions: A Step-By-Step Guide July 14, 2016
1pm-2:30pm EDT, Online Training
More Upcoming Courses